 | Parts of this article (those related to Entire article) need to beupdated. The reason given is: hasn't been materially touched since 2014. Please help update this article to reflect recent events or newly available information.(August 2022) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: RGEN S&P 400 Component | |
| Industry | BiotechnologyLaboratory equipment |
| Founded | 1981; 44 years ago (1981) |
| Founders | Alexander Rich Paul Schimmel |
| Headquarters | Waltham, Massachusetts ,United States |
Key people | Olivier Loeillot (president andCEO [as of 2024])[1] |
| Products | Materials used in the manufacture of biological drugs |
| Revenue |  US$634 million(2024) |
Number of employees | Over 1,900 globally |
| Website | repligen |
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturingbiological drugs.2025 The company is based inWaltham, Massachusetts,2014 and wasincorporated inDelaware in 1981.[2] Apublic company, Repligen is listed on theNASDAQ exchange under the symbol RGEN.[3] As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.
Before 2012, Repligen maintained dual capabilities in developing pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business).[4] A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures.[5] As of 2024, Repligen's product portfolio includes filtration and fluid management,Chromatography, process analytics and proteins, serving a wide range of biologics including monoclonal antibodies (mAbs),Antibody–drug conjugates (ADCs), bispecific antibodies, fusion proteins, mRNA, and cell and gene therapies.
Repligen employs adirect sales model to users of its products in the United States, with some sales throughintermediaries in "certain foreign markets".[6] Repligen now serves a global customer base with significant growth in North America, Europe, and Asia-Pacific.
Repligen's company headquarters are housed together with its manufacturing facility in Waltham, Massachusetts.[7]
Headquartered at Waltham, Massachusetts, Repligen operates across 22 sites globally in the United States, Europe, and Asia Pacific. Growth factor products and the native form of Protein A and recombinant Protein A are manufactured in Sweden; assembly of the OPUS chromatography product line is done in the United States.[8]
Alexander Rich was a co-founder of Repligen and served as Chairman Emeritus[9] of Repligen'sboard of directors. Rich had been a member of the Board since 1981.[10]Paul Schimmel is also a co-founder of Repligen, and he is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology atThe Scripps Research Institute. He used to be the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology atMIT. Tony J. Hunt, who actively serves as executive chairman for the board, was the company's President and Chief Executive Officer from 2015 to 2024.
As of 2024[update], the company'sPresident andChief Executive Officer is Olivier Loeillot.
In 2010, Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre-packed chromatography columns.[11]
In 2011, Repligen acquiredbioproduction assets fromNovozymes, which doubled the company's bioprocessing capabilities.[4]
In 2014, Repligen acquired Alternating Tangential Flow (ATF) system from Refine Technology.[12]
In December 2016, Repligen acquiredTangenX.[13]
in June 2017, Spectrum Laboratories Inc. was acquired.[14]
In May 2019, C Technologies was acquired.[15]
In 2020, ARTeSYN Biosolutions wad acquired, expanding on the company's filtration an chromatography systems strategy.[16]
In June 2021, Polymem S.A. was acquired.[17]
In September 2021, Avitide, Inc. was acquired.[18]
In December 2021, BioFlex Solutions was acquired.[19]
In April 2023, Flexbiosys Inc. was acquired.[20]
In September 2023, Repligen acquired magnetic mixer manufacturer, Metenova.[21]
At the end of 2024, Tantti Laboratory Inc. was acquired.[22]
In 2025, Repligen acquired four process analytics technologies assets from chemical analysis tech firm 908 Devices.[23]
In 2008, an agreement was struck to divest certain intellectual property rights toBristol-Myers Squibb around the drugOrencia in exchange for ongoingroyalty payments through the end of 2013.[4]
At the end of 2012, Repligen out-licensed itsspinal muscular atrophy program, in particular the small molecule candidate drugRG3039, toPfizer.[4] This divestment included licensing rights to two patents to Pfizer.[8][24][25]
At the start of 2014, the company out-licensed itsFriedreich's ataxia program, including a library ofhistone deacetylase inhibitor compounds, toBioMarin Pharmaceutical forUS$2,000,000 and future milestone and royalty payments.[2][26]
Development of animaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by theUSFDA for additional safety and efficacy data beyond that provided in aNew Drug Application (NDA) submission; aMarketing Authorization Application had been submitted in parallel to theEMA.[2]
Repligen was a major supplier ofProtein A, both native and recombinant forms, to the pharmaceutical industry.[4] In 2010-2013, Protein A accounted for the majority of the company's product sales.[11] The company also providesgrowth factors to increase the productivity of cell-basedbioproduction, multiplealternating tangential flow (ATF) systems, and a line (OPUS) ofchromatography columns scaled to manufacture of product for testing inclinical trials.[4]
Today, the company's suite of offerings has been diversified by its many acquisitions and partnerships. In downstream bioprocessing, Repligen offers tangential flow filtration systems (Cross-flow filtration), flat sheet cassettes, hollow fiber filters, single-use components, assemblies, mixers, chromatography systems, pre-packed columns, and resins. Within upstream bioprocessing they offer alternating tangential flow filtration systems (ATF), tangential flow depth filtration systems (TFDF), tangential flow filtration systems and cell culture supplements. Across the entire bioproduction workflow there areProcess analytical technology (PAT) devices offered as standalone solutions or directly integrated onto filtration systems.
Some Repligen products include, but are not limited to:
In 2023, Repligen launched the KrosFlo® RS 10 TFF system, introducing the first laboratory scaletangential flow filtration system built specifically forBiomanufacturing with adherence toCurrent Good Manufacturing Practices (cGMP). During the same year, the company released a self-contained, holder less TFF device called the TangenX® SC.
In 2025, the company launched the CTech™ SoloVPE PLUS System, their UV-based Variable Pathlength Technology system.[27]
